Oracle (NYSE: ORCL) and AstraZeneca announced a partnership to advance AI-enabled healthcare solutions focused on real-world data and clinical research. The collaboration aims to improve identification of eligible patients for clinical trials and to speed up evidence generation from real-world datasets. Both companies plan to link research outputs directly into care delivery workflows across several therapeutic areas, including chronic and complex diseases. The Oracle and AstraZeneca AI-enabled healthcare partnership is a material shift that investors may want to weigh against other findings. Check out 3 warning signs (1 major) that Oracle investors should know about.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.